Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis

Graf, Tilmann; Thiele, Thomas; Klingebiel, Randolf; Greinacher, Andreas; Schäbitz, Wolf-Rüdiger; Greeve, Isabell

Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis

Graf T, Thiele T, Klingebiel R, Greinacher A, Schäbitz W-R, Greeve I (2021)
Journal of Neurology 268(12): 4483-4485.

Zeitschriftenaufsatz | Veröffentlicht | Englisch

Download

Graf2021_Article_ImmediateHigh-doseIntravenousI-1.pdf 673.10 KB

DOI

https://doi.org/10.1007/s00415-021-10599-2

URN

urn:nbn:de:0070-pub-29648259

Autor*in

Graf, Tilmann; Thiele, Thomas; Klingebiel, Randolf; Greinacher, Andreas; Schäbitz, Wolf-Rüdiger^UniBi; Greeve, Isabell^UniBi

Einrichtung

Medizinische Fakultät OWL

Erscheinungsjahr

2021

Zeitschriftentitel

Journal of Neurology

Band

268

Ausgabe

12

Seite(n)

4483-4485

Urheberrecht / Lizenzen

Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0)

ISSN

0340-5354

eISSN

1432-1459

Page URI

https://pub.uni-bielefeld.de/record/2964825

Zitieren

Graf T, Thiele T, Klingebiel R, Greinacher A, Schäbitz W-R, Greeve I. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology. 2021;268(12):4483-4485.

Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W. - R., & Greeve, I. (2021). Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology, 268(12), 4483-4485. https://doi.org/10.1007/s00415-021-10599-2

Graf, Tilmann, Thiele, Thomas, Klingebiel, Randolf, Greinacher, Andreas, Schäbitz, Wolf-Rüdiger, and Greeve, Isabell. 2021. “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”. Journal of Neurology 268 (12): 4483-4485.

Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W. - R., and Greeve, I. (2021). Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology 268, 4483-4485.

Graf, T., et al., 2021. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology, 268(12), p 4483-4485.

T. Graf, et al., “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”, Journal of Neurology, vol. 268, 2021, pp. 4483-4485.

Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W.-R., Greeve, I.: Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology. 268, 4483-4485 (2021).

Graf, Tilmann, Thiele, Thomas, Klingebiel, Randolf, Greinacher, Andreas, Schäbitz, Wolf-Rüdiger, and Greeve, Isabell. “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”. Journal of Neurology 268.12 (2021): 4483-4485.

Alle Dateien verfügbar unter der/den folgenden Lizenz(en):

Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):